TrialGynecologic oncology2023

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

T M Davidson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.